Furthermore, Cenicriviroc for CCL2 [254], Tocilizumab targeting IL-6R [255], Canakinumab for IL-1β [256], Infliximab and nanoparticle based CYT-6091 (under clinical trial) for TNF-α [257,258] can be used as possible anti-inflammatory molecules in BC. The gene discussed is CCL2; the disease is breast cancer.